Assembly Biosciences to Webcast Upcoming Investor Conferences
19 févr. 2016 07h30 HE | Assembly Biosciences, Inc.
INDIANAPOLIS, Feb. 19, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a public biotechnology company advancing a new class of oral biologic drugs for addressing the gut...
Assembly Biosciences Presents Clinical Data at Drug Formulation & Bioavailability Summit Showing Its Oral Gemicel(TM) Technology Achieves Targeted Delivery to the Lower GI Tract
27 janv. 2016 07h30 HE | Assembly Biosciences, Inc.
PHILADELPHIA and INDIANAPOLIS, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing treatments for infectious diseases including hepatitis B...
AssemblyBio_logo_RGB.png
Assembly Biosciences Expands Senior Leadership Team
11 janv. 2016 07h30 HE | Assembly Biosciences, Inc.
INDIANAPOLIS, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus...
AssemblyBio_logo_RGB.png
Assembly Biosciences to Present at Jefferies Microbiome Summit
16 déc. 2015 07h30 HE | Assembly Biosciences, Inc.
INDIANAPOLIS, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus...
AssemblyBio_logo_RGB.png
Clinical Study Shows Assembly Biosciences' Oral Gemicel™ Technology Can Achieve Targeted Delivery to the Lower GI Tract for Microbiome and Other Applications
09 déc. 2015 07h00 HE | Assembly Biosciences, Inc.
—Assembly is Developing Curative Treatments for HBV, Resistant C. difficile Infections (CDI) and Other Infectious Diseases— —Expects to Initiate Phase lb Trial in 2016 Using Gemicel to Deliver...
OpenBiome logo
Fecal transplant pills: Large-scale production begins
28 oct. 2015 08h39 HE | OpenBiome
BOSTON, Oct. 28, 2015 (GLOBE NEWSWIRE) -- A new pill created by a team of MIT-trained researchers provides fecal transplant therapy without requiring the traditional, more invasive stool delivery...
C3 Jian Completes Second Phase 2 Clinical Trial of Anti-Cavity Drug
13 juil. 2015 06h00 HE | C3 Jian, Inc.
LOS ANGELES, July 13, 2015 (GLOBE NEWSWIRE) -- C3 Jian, Inc., a biotechnology company focused on reengineering the human microbiome to deliver novel healthcare products, announced it has preliminary...
Microbiome Revolution to Usher in 'Designer' Food, and Transform Well-Being
27 mai 2014 07h30 HE | Lux Research
BOSTON, MA--(Marketwired - May 27, 2014) - Over 100 trillion microbes live in and on the human body, predominantly in the digestive tract, comprising our "microbiome." Scientists are now starting to...